Date: 2015-01-20
Type of information: Initiation of the trial
phase:
Announcement: initiation of the trial
Company: VolitionRx (Singapore) Singapore General Hospital (Singapore)
Product: NuQ® assays
Action
mechanism: VolitionRx\'s NuQ® tests utilize the Company\'s proprietary Nucleosomics® platform, which identifies and measures circulating nucleosome structures for the presence of epigenetic cancer signals within the blood.
Disease: ovarian cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On January 20, 2015, VolitionRx, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, announced it has signed an agreement to commence a pilot ovarian cancer study in collaboration with Singapore General Hospital (SGH). Blood and tissue samples collected from 40 patients will be assessed to establish the feasibility of VolitionRx\'s proprietary NuQ® assays in detecting ovarian cancer. If this test proves to be accurate, it could offer hope as an early-stage screening tool. The collaboration with SGH will be VolitionRx\'s first to focus solely on patients from an Asian ethnic background. The Hospital will provide 20 matched blood and tissue samples from patients with ovarian cancer as well as blood samples from 20 healthy donors. The anonymised and blinded samples will be analysed by VolitionRx\'s team and will be the first matched tissue and blood samples to be assessed using its NuQ® assays. On completion of the analyses, the data will be unblinded and together the parties will evaluate the performance of the test. VolitionRx will retain the intellectual property from the study.
